Drugs / AMSCs
AMSCs
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06280092 | Dec 2024 → Mar 2026 overdue | epilepsy | Sanjeet S. Grewal | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04212728 | Dec 2019 → Dec 2023 | osteoarthritis, knee | Yantai Yuhuangding Hospital | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMSCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04212728 ↗ |
| Known as | Allogenic Adipose-derived Mesenchymal Stem Cells | “Allogenic Adipose-derived Mesenchymal Stem Cells(AMSCs) for Epilepsy During Deep Brain Stimulation(DBS) Surgery” NCT06280092 ↗ |
| Known as | autologous adipose-derived mesenchymal stem cells | “autologous adipose-derived mesenchymal stem cells (AMSCs)” NCT04212728 ↗ |
| Known as | MSCs | “Allogenic Adipose-derived Mesenchymal Stem Cells(AMSCs) for Epilepsy During Deep Brain Stimulation(DBS) Surgery” NCT06280092 ↗ |
| Modality | Cell therapy | “autologous adipose-derived mesenchymal stem cells (AMSCs)” NCT04212728 ↗ |
| Route | Other | “infused via intraparenchymal” NCT06280092 ↗ |